Alnylam Pharmaceuticals (ALNY) Gross Profit (2018 - 2026)

Alnylam Pharmaceuticals has reported Gross Profit for 9 years, with the latest figure at $959.7 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 2488.21% year-over-year to $959.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 billion (up 137.54% YoY), and the FY2025 full-year result was $3.0 billion, up 56.4% from the prior year.
• Gross Profit for Q1 2026 stood at $959.7 million, up from $829.3 million in the prior quarter.
• The five-year high for Gross Profit was $1.1 billion in Q3 2025, with the low at -$40.2 million in Q1 2025.
• Historically, Gross Profit has averaged $460.7 million across 5 years, with a median of $418.9 million in 2024.
• Annual changes were most pronounced in 2025 — Gross Profit slumped 109.14% — and 2026, when it jumped 2488.21%.
• Alnylam Pharmaceuticals' Gross Profit stood at $288.9 million in 2022, then rose by 27.31% to $367.7 million in 2023, then surged by 33.39% to $490.5 million in 2024, then jumped by 69.07% to $829.3 million in 2025, then increased by 15.72% to $959.7 million in 2026.
• The last three Gross Profit figures came in at $959.7 million (Q1 2026), $829.3 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.